INTRODUCTION: Circulating microparticles (MPs) may trigger a hypercoagulable state, leading to thrombotic complications. Data on their association with venous thromboembolism (VTE) are few and inconsistent. MATERIALS AND METHODS: To investigate whether or not high levels of MPs are associated with an increased risk of VTE, we carried out a case-control study on 186 patients with a first, objectively diagnosed, episode of VTE and 418 healthy controls. Plasma levels of circulating MPs were measured by flow cytometry. RESULTS: Patients had higher median plasma levels of total MPs than controls (2184 per μL vs 1769 per μL, p<0.0001). The risk of VTE increased progressively with increasing MPs, with a linear dose-response effect in the log odds. Individuals with MPs above the 90th percentile of the controls' distribution (P(90) = 3263 per μL) had a 5-fold increased risk of VTE than those with MPs below the 10th percentile of controls (P(10) = 913 per μL), independently of sex, age, body mass index, thrombophilia, and plasma factor VIII levels [adjusted odds ratio: 5.30 (95%CI: 2.05-13.7)]. Using the 95th percentile of controls as cut-off (P(95) = 4120 per μL), the adjusted odds ratio was 2.20 (1.01-4.79) for individuals with MPs>P(95) compared with those having MPs ≤ P(95). After exclusion of individuals with antiphospholipid antibodies and hyperhomocysteinemia, the interaction between MPs>P(95) and thrombophilia increased the VTE risk from 1.63 (0.60-4.50) to 6.09 (1.03-36.1). CONCLUSIONS: High levels of circulating MPs are a possible independent risk factor for VTE.
INTRODUCTION: Circulating microparticles (MPs) may trigger a hypercoagulable state, leading to thrombotic complications. Data on their association with venous thromboembolism (VTE) are few and inconsistent. MATERIALS AND METHODS: To investigate whether or not high levels of MPs are associated with an increased risk of VTE, we carried out a case-control study on 186 patients with a first, objectively diagnosed, episode of VTE and 418 healthy controls. Plasma levels of circulating MPs were measured by flow cytometry. RESULTS:Patients had higher median plasma levels of total MPs than controls (2184 per μL vs 1769 per μL, p<0.0001). The risk of VTE increased progressively with increasing MPs, with a linear dose-response effect in the log odds. Individuals with MPs above the 90th percentile of the controls' distribution (P(90) = 3263 per μL) had a 5-fold increased risk of VTE than those with MPs below the 10th percentile of controls (P(10) = 913 per μL), independently of sex, age, body mass index, thrombophilia, and plasma factor VIII levels [adjusted odds ratio: 5.30 (95%CI: 2.05-13.7)]. Using the 95th percentile of controls as cut-off (P(95) = 4120 per μL), the adjusted odds ratio was 2.20 (1.01-4.79) for individuals with MPs>P(95) compared with those having MPs ≤ P(95). After exclusion of individuals with antiphospholipid antibodies and hyperhomocysteinemia, the interaction between MPs>P(95) and thrombophilia increased the VTE risk from 1.63 (0.60-4.50) to 6.09 (1.03-36.1). CONCLUSIONS: High levels of circulating MPs are a possible independent risk factor for VTE.
Authors: Satbir K Dhillon; Mindy L Houck; Donald H Jenkins; Jordan K Rosedahl; William S Harmsen; Timothy M Halling; Myung S Park Journal: J Trauma Acute Care Surg Date: 2014-11 Impact factor: 3.313
Authors: Lisa Ayers; Anne-Christin Stoewhas; Berne Ferry; Tsogyal D Latshang; Christian M Lo Cascio; Ross Sadler; Katrin Stadelmann; Noemi Tesler; Reto Huber; Peter Achermann; Konrad E Bloch; Malcolm Kohler Journal: Eur J Appl Physiol Date: 2014-02-11 Impact factor: 3.078